Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
Status:
Recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
This is single center, open-label phase 1 dose escalation trial that uses modified 3+3 design
to identify a recommended phase 2 dose (RP2D) of CAR.B7-H3 T cell product. An expansion
cohort will enroll additional subjects at the RP2D for a total enrollment of up to 21
subjects on the protocol.